Skye Bioscience, Inc. (SKYE)
Automate Your Wheel Strategy on SKYE
With Tiblio's Option Bot, you can configure your own wheel strategy including SKYE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SKYE
- Rev/Share 0.0
- Book/Share 1.1013
- PB 1.7252
- Debt/Equity 0.0084
- CurrentRatio 6.0857
- ROIC -1.1397
- MktCap 58877960.0
- FreeCF/Share -0.8811
- PFCF -1.685
- PE -1.7784
- Debt/Assets 0.007
- DivYield 0
- ROE -0.6865
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | SKYE | Cantor Fitzgerald | Overweight | Neutral | -- | $2 | Oct. 6, 2025 |
| Downgrade | SKYE | Craig Hallum | Buy | Hold | -- | $2 | Oct. 6, 2025 |
| Initiation | SKYE | Evercore ISI | -- | Outperform | -- | $10 | Aug. 15, 2025 |
| Initiation | SKYE | William Blair | -- | Outperform | -- | -- | Feb. 28, 2025 |
| Initiation | SKYE | Scotiabank | -- | Sector Outperform | -- | $20 | Sept. 30, 2024 |
| Initiation | SKYE | JMP Securities | -- | Mkt Outperform | -- | $15 | Sept. 10, 2024 |
News
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Skye Bioscience stock nosedives 60% after its investigational obesity candidate, nimacimab, fails to meet the key goal in a mid-stage study.
Read More
Skye Bioscience, Inc. - Special Call
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Skye Bioscience, Inc. - Special Call Company Participants Bernie Hertel Punit Dhillon - President, CEO, Secretary & Director Puneet Arora - Chief Medical Officer Tu Diep - Chief Operating Officer Christopher Twitty - Chief Scientific Officer Conference Call Participants Jay Olson - Oppenheimer & Co. Inc., Research Division Louis Aronne Michael DiFiore - Evercore ISI Institutional Equities, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Sean Wharton Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Gum-Ming Lowe - Craig-Hallum Capital Group LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Ananda Ghosh …
Read More
Skye Bioscience: Promising Nimacimab Data Supports Buy Rating
Published: October 01, 2025 by: Seeking Alpha
Sentiment: Positive
Skye Bioscience is rated Buy, driven by nimacimab's strong safety, durable weight-loss profile, and upcoming Phase 2a results. SKYE's nimacimab targets the expanding anti-obesity market, showing potential as monotherapy, combination, or maintenance therapy, with favorable early data. Risks include clinical trial uncertainties, manufacturing reliance, and regulatory scrutiny, but SKYE's cash runway extends through Q1 2027, supporting key milestones.
Read More
Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Skye Bioscience, Inc. (NASDAQ:SKYE ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 7:00 AM EDT Company Participants Punit Dhillon - President, CEO, Secretary & Director Conference Call Participants Frank Tang - Morgan Stanley Presentation Frank Tang Managing Director Good morning, everyone. My name is Frank Tang, and I'm with the Investment Banking division at Morgan Stanley.
Read More
Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Virtual KOL event will begin at 8:00 AM ET on Thursday, September 4, 2025 Virtual KOL event will begin at 8:00 AM ET on Thursday, September 4, 2025
Read More
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, August 7, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its second quarter 2025 financial results. The Company will issue its financial results and business update press release after the market closes on the same day.
Read More
Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the debut of its “Anatomy of Progress” nimacimab development update video series and availability of presentations related to the development of its anti-obesity drug, nimacimab, presented in multiple forums at the American Diabetes Association's (ADA) 85th Scientific Sessions held June 20-23, 2025, in Chicago, Illinois. The presentations are accessible at the following link.
Read More
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
Read More
About Skye Bioscience, Inc. (SKYE)
- IPO Date 2014-11-26
- Website https://skyebioscience.com
- Industry Biotechnology
- CEO Punit S. Dhillon
- Employees 16